Influenza Clinical Trial Landscape
Data updated: May 20, 2026
1,166 clinical trials tracked since 2008
Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and lungs. It affects people of all ages and represents a significant public health concern globally. Clinical trial activity for influenza remains robust, with 1,166 trials registered since 2008. Currently, 89 trials are actively recruiting, enrolling, or active but not recruiting participants. These active trials span all phases of clinical development, with 29 in Phase 1, 25 in Phase 2, 23 in Phase 3, and 19 in Phase 4. A review of the total trial distribution by phase shows a fairly even distribution of trials across Phase 1, 2, and 3, with Phase 4 trials being less common. Industry sponsors with the most active influenza trials include GSK with 4 active trials, followed by Changchun BCHT Biotechnology Co. with 3, and Sanofi, Valenta Pharm JSC, and Shanghai Institute Of Biological Products each sponsoring 2 active trials.
86 active
/
1166 total (since 2008)
29
Phase 1 Active
330 total
25
Phase 2 Active
365 total
22
Phase 3 Active
326 total
17
Phase 4 Active
244 total
Top Industry Sponsors
Sorted by active Active Done Failed
GSK 4 102 8
Changchun BCHT Biotechnology Co. 3 1 0
Sanofi 2 63 2
Valenta Pharm JSC 2 10 0
Shanghai Institute Of Biological Products 2 8 0
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT06653569 RECRUITING
Efficacy of Baloxavir Against Influenza in Hospitalized Patients: The INFLUENT Study (INpatients inFLUENza Treatment)
Dre Pauline Vetter n=484
NCT06094010 RECRUITING
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
Hoffmann-La Roche n=1,100
NCT07496736 ACTIVE NOT RECRUITING
Post-exposure Influenza Prophylaxis in a Hospital Setting
University Medical Centre Ljubljana n=200
NCT06087640 ACTIVE NOT RECRUITING
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Seqirus n=35,800
NCT07496450 RECRUITING
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
ModernaTX, Inc. n=4,000
+ 321 more Phase 3 trials — see full database below
Influenza — Trials Started by Year (last 10 years)
2016 54
2017 46
2018 53
2019 41
2020 29
2021 38
2022 49
2023 43
2024 38
2025 47
2026 15
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
GSK 114
Changchun BCHT Biotechnology Co. 4
Sanofi 67
Valenta Pharm JSC 12
Shanghai Institute Of Biological Products 10
Jiangxi Qingfeng Pharmaceutical Co. Ltd. 6
Guangdong Raynovent Biotech Co., Ltd 5
Traws Pharma, Inc. 2
Seqirus 44
ModernaTX, Inc. 21
Active Trials by Phase
Phase 1 29
Phase 2 25
Phase 3 22
Phase 4 17
Enrollment Size Distribution
1-50 183
51-200 398
201-500 251
501-1k 129
1k+ 181
All Industry Sponsors
Sorted by active Active Done Failed
GSK 4 102 8
Changchun BCHT Biotechnology Co. 3 1 0
Sanofi 2 63 2
Valenta Pharm JSC 2 10 0
Shanghai Institute Of Biological Products 2 8 0
Jiangxi Qingfeng Pharmaceutical Co. Ltd. 2 4 0
Guangdong Raynovent Biotech Co., Ltd 2 3 0
Traws Pharma, Inc. 2 0 0
Seqirus 1 42 1
ModernaTX, Inc. 1 20 0
Roche 1 13 2
Sinovac Biotech Co., Ltd 1 13 0
Osivax 1 6 0
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 1 2 0
Vaxine Pty Ltd 1 2 0
NCT06653569 RECRUITING
Efficacy of Baloxavir Against Influenza in Hospitalized Patients: The INFLUENT Study (INpatients inFLUENza Treatment)
Dre Pauline Vetter n=484
NCT06094010 RECRUITING
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
Hoffmann-La Roche n=1,100
NCT07496736 ACTIVE NOT RECRUITING
Post-exposure Influenza Prophylaxis in a Hospital Setting
University Medical Centre Ljubljana n=200
NCT06087640 ACTIVE NOT RECRUITING
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Seqirus n=35,800
NCT07496450 RECRUITING
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
ModernaTX, Inc. n=4,000
NCT07485855 RECRUITING
Influenza Vaccination Strategy for Patients With Hematologic Malignancy
Asan Medical Center n=60
NCT07236814 RECRUITING
Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting
Capital Medical University n=384
NCT07159763 RECRUITING
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=7,500
NCT07211152 RECRUITING
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women
Sinovac Biotech Co., Ltd n=150
NCT07351500 NOT YET RECRUITING
Adaptive RCT of Corticosteroids for Severe Influenza Pneumonia in Adults
Qingyuan Zhan n=496
NCT07314905 NOT YET RECRUITING
Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)
Unity Health Toronto n=264
NCT07240558 RECRUITING
Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)
University Health Network, Toronto n=120
NCT07229807 ACTIVE NOT RECRUITING
Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A
Guangdong Raynovent Biotech Co., Ltd n=119
NCT07229820 ACTIVE NOT RECRUITING
Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A
Guangdong Raynovent Biotech Co., Ltd n=157
NCT07229547 NOT YET RECRUITING
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Onradivir Tablets in Participants Aged 12 to 17 Years With Uncomplicated Influenza A.
Ruijin Hospital n=150
NCT07133802 NOT YET RECRUITING
Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
Changchun BCHT Biotechnology Co. n=6,680
NCT07113392 NOT YET RECRUITING
A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension
Jiangxi Kvvit Pharmaceutical Co., Ltd. n=144
NCT06528444 RECRUITING
Clinical Trial Evaluating the Efficacy and Safety of Dexamethasone Compared to Placebo in Patients With Severe Influenza
Instituto de Investigación Sanitaria y Biomédica de Alicante n=42
NCT06817096 NOT YET RECRUITING
Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza
Azidus Brasil n=340
NCT06800950 NOT YET RECRUITING
Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine
Institute of Medical Biology, Chinese Academy of Medical Sciences n=4,400
NCT06574503 RECRUITING
Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza
Jiangxi Qingfeng Pharmaceutical Co. Ltd. n=748
NCT06573008 RECRUITING
Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications
Jiangxi Qingfeng Pharmaceutical Co. Ltd. n=328
NCT06774859 COMPLETED
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms
Hoffmann-La Roche n=100
NCT04682444 COMPLETED
Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.
Joint Stock Company "Farmak" n=100
NCT00782431 COMPLETED
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Alachua Government Services, Inc. n=3,208
NCT05645900 COMPLETED
A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months
Ab&B Bio-tech Co., Ltd.JS n=2,772
NCT04544267 TERMINATED
Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age
Sanofi Pasteur, a Sanofi Company n=100
NCT06178991 COMPLETED
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
BioNTech SE n=8,795
NCT06641180 COMPLETED
Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age
Sanofi Pasteur, a Sanofi Company n=1,180
NCT06694389 COMPLETED
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ���50 Years of Age
ModernaTX, Inc. n=2,457
NCT00800605 COMPLETED
Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
Alachua Government Services, Inc. n=7,250
NCT01687517 COMPLETED
Efficacy and Safety of Influenza Vaccine During Sarcoidosis
Assistance Publique - Hôpitaux de Paris n=190
NCT06507813 COMPLETED
Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza
Jiaxing AnDiCon Biotech Co.,Ltd n=190
NCT05118672 COMPLETED
Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment
Eurofarma Laboratorios S.A. n=567
NCT05779020 COMPLETED
Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .
Butantan Institute n=1,373
NCT04210349 COMPLETED
Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age
Sanofi Pasteur, a Sanofi Company n=7,106
NCT01773928 COMPLETED
Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)
Alachua Government Services, Inc. n=1,928
NCT06602024 COMPLETED
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. n=40,817
NCT06049927 COMPLETED
A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months
Sinovac Biotech Co., Ltd n=3,300
NCT05827978 COMPLETED
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
ModernaTX, Inc. n=8,411
NCT03969212 COMPLETED
Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households
Hoffmann-La Roche n=4,138
NCT06097273 COMPLETED
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
ModernaTX, Inc. n=8,061
NCT06054269 COMPLETED
Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP
Centers for Disease Control and Prevention n=192
NCT05071313 COMPLETED
A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older
Janssen Vaccines & Prevention B.V. n=777
NCT05540522 COMPLETED
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
Pfizer n=45,789
NCT06183229 COMPLETED
Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza
POLYSAN Scientific & Technological Pharmaceutical Company n=166
NCT06015282 COMPLETED
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older
Seqirus n=7,741
NCT05170009 TERMINATED
Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza
Weill Medical College of Cornell University n=2
NCT03927131 COMPLETED
Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine
Butantan Institute n=5,822
NCT03376321 TERMINATED
A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection
Janssen Research & Development, LLC n=334
NCT03381196 TERMINATED
A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications
Janssen Research & Development, LLC n=553
NCT05566639 COMPLETED
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
ModernaTX, Inc. n=22,502
NCT02839330 COMPLETED
A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
Seqirus n=3,196
NCT05702489 COMPLETED
A Study to Evaluate the Efficacy and Safety of ZX-7101A Tablets in Adults with Uncomplicated Influenza
Nanjing Zenshine Pharmaceuticals n=900
NCT03849560 COMPLETED
Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers
NPO Petrovax n=612
NCT05415462 COMPLETED
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
ModernaTX, Inc. n=6,102
NCT05245552 COMPLETED
A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months
Sinovac Biotech Co., Ltd n=217
NCT05431725 COMPLETED
Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Sinovac Biotech Co., Ltd n=2,202
NCT03653364 COMPLETED
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms
Hoffmann-La Roche n=49
NCT06385821 COMPLETED
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
NPO Petrovax n=824
NCT05642078 COMPLETED
Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. n=2,550
NCT03744104 COMPLETED
A Clinical Trial of A Quadrivalent Influenza Vaccine
Shanghai Institute Of Biological Products n=2,688
NCT05474755 COMPLETED
To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection
Jiangxi Qingfeng Pharmaceutical Co. Ltd. n=591
NCT01227421 COMPLETED
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
Romark Laboratories L.C. n=624
NCT01551823 COMPLETED
The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) （Children Forms of Drug）
Institute of Medical Biology, Chinese Academy of Medical Sciences n=1,200
NCT01551810 COMPLETED
The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)
Institute of Medical Biology, Chinese Academy of Medical Sciences n=1,200
NCT05544916 COMPLETED
A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections
Valenta Pharm JSC n=260
NCT05044195 COMPLETED
A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age
Seqirus n=2,044
NCT02677493 COMPLETED
Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'
Il-Yang Pharm. Co., Ltd. n=1,794
NCT04250311 SUSPENDED
Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults
Materia Medica Holding n=314
NCT03301051 COMPLETED
Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults
Medicago n=10,160
NCT03321968 COMPLETED
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
Medicago n=1,202
NCT05269290 COMPLETED
Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections
Valenta Pharm JSC n=240
NCT05273619 COMPLETED
Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection
Valenta Pharm JSC n=250
NCT04695717 COMPLETED
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
Vietnam Military Medical University n=864
NCT04683406 COMPLETED
A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A
Guangdong Raynovent Biotech Co., Ltd n=750
NCT05869201 COMPLETED
Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine
St. Petersburg Research Institute of Vaccines and Sera n=450
NCT01964989 COMPLETED
Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.
Seqirus n=10,644
NCT02255409 COMPLETED
Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05
Seqirus n=607
NCT05069714 COMPLETED
One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis.
Seoul National University Hospital n=184
NCT05308212 COMPLETED
Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra
St. Petersburg Research Institute of Vaccines and Sera n=633
NCT05470582 COMPLETED
Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old
St. Petersburg Research Institute of Vaccines and Sera n=1,066
NCT05457894 COMPLETED
Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women
St. Petersburg Research Institute of Vaccines and Sera n=207
NCT03336619 COMPLETED
A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza
Romark Laboratories L.C. n=1,030
NCT05417997 COMPLETED
Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients
RAAS Nutritionals, LLC n=71
NCT03704740 COMPLETED
Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months
SK Bioscience Co., Ltd. n=676
NCT03765437 COMPLETED
Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam
Sanofi Pasteur, a Sanofi Company n=230
NCT03391193 COMPLETED
Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine
Sanofi Pasteur, a Sanofi Company n=301
NCT02451358 COMPLETED
Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India
Sanofi Pasteur, a Sanofi Company n=400
NCT05317767 COMPLETED
The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.
St. Petersburg Research Institute of Vaccines and Sera n=600
NCT03282240 COMPLETED
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Sanofi Pasteur, a Sanofi Company n=2,670
NCT05312294 COMPLETED
Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Years
St. Petersburg Research Institute of Vaccines and Sera n=654
NCT02550197 COMPLETED
Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years
Sanofi Pasteur, a Sanofi Company n=300
NCT01034254 COMPLETED
Field Trial of Maternal Influenza Immunization in Asia
Children's Hospital Medical Center, Cincinnati n=3,693
NCT04074928 COMPLETED
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
Seqirus n=2,414
NCT05089123 COMPLETED
The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old
St. Petersburg Research Institute of Vaccines and Sera n=320
NCT01310413 COMPLETED
Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age
GlaxoSmithKline n=842
NCT01711736 COMPLETED
Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age
GlaxoSmithKline n=606
NCT03450915 COMPLETED
A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine
BiondVax Pharmaceuticals ltd. n=12,460
NCT00841763 COMPLETED
Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects
Novartis n=3,647
NCT02635724 COMPLETED
Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
BioCryst Pharmaceuticals n=74
NCT04806529 WITHDRAWN
An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older
Seqirus
NCT02369159 COMPLETED
Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza
BioCryst Pharmaceuticals n=137
NCT00610935 TERMINATED
Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza
BioCryst Pharmaceuticals n=82
NCT02387294 COMPLETED
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents
Fluart Innovative Vaccine Ltd, Hungary n=120
NCT01161264 COMPLETED
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects
Novartis Vaccines n=126
NCT01051661 COMPLETED
Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age
GlaxoSmithKline n=6,154
NCT03684044 COMPLETED
Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza
Hoffmann-La Roche n=363
NCT03699839 COMPLETED
Reducing the Burden of Influenza After Solid-Organ Transplantation
Oriol Manuel n=619
NCT00929331 COMPLETED
Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years
GlaxoSmithKline n=110
NCT01157702 COMPLETED
Yearly Strain Variation Study, 2010/2011
Alachua Government Services, Inc. n=110
NCT03139565 COMPLETED
High Dose vs. Standard Influenza Vaccine in Adult SOT
University Health Network, Toronto n=172
NCT03165617 COMPLETED
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age
Seqirus n=4,514
NCT03314662 COMPLETED
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
Seqirus n=1,778
NCT01788228 COMPLETED
Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
GlaxoSmithKline n=50
NCT02587221 COMPLETED
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
Seqirus n=6,790
NCT03445468 COMPLETED
Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents
Il-Yang Pharm. Co., Ltd. n=379
NCT02467842 COMPLETED
Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects
SK Chemicals Co., Ltd. n=1,503
NCT03629184 COMPLETED
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms
Hoffmann-La Roche n=173
NCT03390166 COMPLETED
Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults
Mahidol University n=945
NCT00971906 COMPLETED
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
Novartis Vaccines n=660
NCT02949011 COMPLETED
Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications
Shionogi n=2,184
NCT00968539 COMPLETED
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
GlaxoSmithKline n=130
NCT02287467 COMPLETED
Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza
National Institute of Allergy and Infectious Diseases (NIAID) n=329
NCT03460743 COMPLETED
Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.
Laboratorios Liomont n=1,556
NCT04101435 COMPLETED
Immunogenicity and Safety Evaluation of QIS in Healthy Subjects
Adimmune Corporation n=174
NCT03718468 COMPLETED
A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine
Medigen Vaccine Biologics Corp. n=842
NCT03095599 COMPLETED
Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3
Institute of Vaccines and Medical Biologicals, Vietnam n=889
NCT00718120 COMPLETED
Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years
GlaxoSmithKline n=110
NCT00972517 COMPLETED
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
GlaxoSmithKline n=245
NCT00989287 COMPLETED
Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults
GlaxoSmithKline n=131
NCT02572817 COMPLETED
Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
National Institute of Allergy and Infectious Diseases (NIAID) n=138
NCT00968526 COMPLETED
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
GlaxoSmithKline n=240
NCT02256488 COMPLETED
Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects
Novartis Vaccines n=1,561
NCT02612909 COMPLETED
A Safety and Immunogenicity Study of IVACFLU-A/H5N1
Institute of Vaccines and Medical Biologicals, Vietnam n=930
NCT02954354 COMPLETED
A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Shionogi n=1,436
NCT02583256 COMPLETED
Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)
Seqirus n=1,601
NCT02935192 COMPLETED
Phase 3 Trial of Serbian Seasonal Influenza Vaccine
Institute of Virology, Vaccines and Sera, Torlak n=480
NCT00975884 COMPLETED
Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults
GlaxoSmithKline n=312
NCT03859141 COMPLETED
Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)
Sinovac Biotech Co., Ltd n=2,340
NCT03853993 COMPLETED
Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)
Sinovac Biotech Co., Ltd n=2,380
NCT00992511 COMPLETED
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes
GlaxoSmithKline n=300
NCT01533220 COMPLETED
Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal
EMS n=132
NCT02914275 COMPLETED
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
Seqirus n=2,250
NCT00803595 COMPLETED
A Multinational Phase III Study of CS-8958 (MARVEL)
Daiichi Sankyo Co., Ltd. n=1,002
NCT01231620 COMPLETED
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
GlaxoSmithKline n=626
NCT01439360 COMPLETED
An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children
GlaxoSmithKline n=12,046
NCT01144299 COMPLETED
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
GlaxoSmithKline n=114
NCT01204671 COMPLETED
Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)
GlaxoSmithKline n=4,659
NCT01196975 COMPLETED
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
GlaxoSmithKline n=1,707
NCT00992784 COMPLETED
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People
GlaxoSmithKline n=370
NCT00980005 COMPLETED
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
GlaxoSmithKline n=2,116
NCT01198756 COMPLETED
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children
GlaxoSmithKline n=3,109
NCT01014091 TERMINATED
Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children
GlaxoSmithKline n=60
NCT00920374 COMPLETED
A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in Adults
GlaxoSmithKline n=118
NCT01196988 COMPLETED
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
GlaxoSmithKline n=3,027
NCT01884519 COMPLETED
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older
GlaxoSmithKline n=120
NCT01440387 COMPLETED
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
GlaxoSmithKline n=112
NCT01626820 COMPLETED
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults
GlaxoSmithKline n=113
NCT01379937 COMPLETED
A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children
GlaxoSmithKline n=520
NCT01702454 COMPLETED
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345
GlaxoSmithKline n=470
NCT02242643 COMPLETED
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age
GlaxoSmithKline n=2,432
NCT01878825 COMPLETED
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older
GlaxoSmithKline n=121
NCT01607112 COMPLETED
A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above
GlaxoSmithKline n=119
NCT01878812 COMPLETED
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and Older
GlaxoSmithKline n=117
NCT00938392 COMPLETED
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly
GlaxoSmithKline n=726
NCT00812981 COMPLETED
A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine.
GlaxoSmithKline n=320
NCT00971425 COMPLETED
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
GlaxoSmithKline n=145
NCT00706563 COMPLETED
A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in Adults
GlaxoSmithKline n=120
NCT00760617 COMPLETED
Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older
GlaxoSmithKline n=526
NCT01306669 COMPLETED
Influenza Vaccine Trial in HIV Uninfected Pregnant Women
University of Witwatersrand, South Africa n=2,116
NCT00979407 COMPLETED
Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)
GlaxoSmithKline n=336
NCT00652743 COMPLETED
Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules
GlaxoSmithKline n=845
NCT01218308 COMPLETED
A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children
GlaxoSmithKline n=5,220
NCT00764790 COMPLETED
Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children
GlaxoSmithKline n=3,317
NCT00772889 COMPLETED
Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly
GlaxoSmithKline n=971
NCT00765076 COMPLETED
Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older
GlaxoSmithKline n=192
NCT01759654 COMPLETED
A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects
Adimmune Corporation n=120
NCT01755364 COMPLETED
A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old
Adimmune Corporation n=122
NCT00545532 COMPLETED
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
Hoffmann-La Roche n=228
NCT03572491 COMPLETED
Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine
Research Institute for Biological Safety Problems n=2,000
NCT00753272 COMPLETED
Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older
GlaxoSmithKline n=43,695
NCT00616928 COMPLETED
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
GlaxoSmithKline n=4,561
NCT01153685 COMPLETED
Immunogenicity & Safety Study of Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years
GlaxoSmithKline n=120
NCT02207413 COMPLETED
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children
GlaxoSmithKline n=1,886
NCT00707941 COMPLETED
Oseltamivir Randomised Controlled Efficacy Trial
International Centre for Diarrhoeal Disease Research, Bangladesh n=1,190
NCT02545543 COMPLETED
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age
Seqirus n=2,278
NCT02612922 COMPLETED
Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
Romark Laboratories L.C. n=325
NCT02218697 COMPLETED
Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older
GlaxoSmithKline n=357
NCT01610245 COMPLETED
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
Romark Laboratories L.C. n=1,941
NCT00979602 COMPLETED
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
GlaxoSmithKline n=4,048
NCT03441373 COMPLETED
XC8 in the Treatment of Patients With Acute Respiratory Viral Infection
PHARMENTERPRISES LLC n=320
NCT01527110 COMPLETED
A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection
GlaxoSmithKline n=21
NCT00964158 COMPLETED
Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)
GlaxoSmithKline n=210
NCT03020628 COMPLETED
Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months
SK Chemicals Co., Ltd. n=171
NCT02285998 COMPLETED
Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age
Protein Sciences Corporation n=9,003
NCT02369341 COMPLETED
Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above
GlaxoSmithKline n=121
NCT01961947 COMPLETED
Study of ASP7374, Cell-culture-derived Influenza Vaccine
UMN Pharma Inc. n=900
NCT01767896 COMPLETED
Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine
UMN Pharma Inc. n=1,020
NCT02366962 COMPLETED
A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older
UMN Pharma Inc. n=55
NCT01319955 COMPLETED
Flu Vaccine Against Childhood Pneumonia, Bangladesh
International Centre for Diarrhoeal Disease Research, Bangladesh n=3,508
NCT02692859 COMPLETED
A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine
Jiangsu Province Centers for Disease Control and Prevention n=1,992
NCT02964065 COMPLETED
A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)
Changchun BCHT Biotechnology Co. n=9,000
NCT03206346 COMPLETED
Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.
Valenta Pharm JSC n=161
NCT03191097 COMPLETED
Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.
Valenta Pharm JSC n=310
NCT03189537 COMPLETED
Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections
Valenta Pharm JSC n=400
NCT00996307 COMPLETED
Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months
Novartis Vaccines n=654
NCT02917304 COMPLETED
A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older
Green Cross Corporation n=274
NCT00959049 COMPLETED
A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population
Seqirus n=1,474
NCT01998477 COMPLETED
A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications
Novartis Vaccines n=430
NCT00945841 COMPLETED
Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010
Novartis n=126
NCT02214225 COMPLETED
A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.
Seqirus n=3,484
NCT01880697 COMPLETED
Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above
Novartis Vaccines n=126
NCT02255279 COMPLETED
Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.
Novartis Vaccines n=287
NCT02381418 COMPLETED
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season
Abbott n=120
NCT00970177 COMPLETED
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
Novartis Vaccines n=812
NCT01210898 COMPLETED
Immunogenicity and Safety of V70P5 Revaccination Subjects
Novartis Vaccines n=197
NCT01000207 COMPLETED
Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects
Novartis Vaccines n=123
NCT00848029 COMPLETED
Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules
Novartis Vaccines n=240
NCT00996138 COMPLETED
Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects
Novartis Vaccines n=200
NCT00735410 COMPLETED
Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009
Novartis Vaccines n=134
NCT00971100 COMPLETED
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age
Novartis Vaccines n=752
NCT02541253 COMPLETED
A Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children
Green Cross Corporation n=543
NCT02091908 COMPLETED
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions
Seqirus n=540
NCT02290509 COMPLETED
Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age
Protein Sciences Corporation n=1,350
NCT01160237 TERMINATED
Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM
GlaxoSmithKline n=7
NCT01959945 COMPLETED
Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)
Protein Sciences Corporation n=219
NCT02710409 COMPLETED
A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older
Jiangsu Province Centers for Disease Control and Prevention n=3,664
NCT00949533 COMPLETED
A Study on Emergence of Resistance With Oseltamivir (Tamiflu) in Participants With Seasonal Influenza
Hoffmann-La Roche n=37
NCT02644018 COMPLETED
Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.
Valenta Pharm JSC n=190
NCT02107807 COMPLETED
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine
Seqirus n=539
NCT00772109 COMPLETED
Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults
Sanofi Pasteur, a Sanofi Company n=4,292
NCT00972816 COMPLETED
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)
Novartis Vaccines n=1,357
NCT01640314 COMPLETED
Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
Novartis Vaccines n=126
NCT02665351 COMPLETED
Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections
Chinese University of Hong Kong n=16
NCT01967784 COMPLETED
Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan
Sanofi Pasteur, a Sanofi Company n=100
NCT01750814 COMPLETED
To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC3102C' Administered Intramuscularly in Healthy Adults
Green Cross Corporation n=400
NCT01992094 COMPLETED
Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older
Novartis Vaccines n=2,680
NCT01992107 COMPLETED
Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old
Novartis Vaccines n=2,333
NCT00973349 COMPLETED
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults
Novartis n=2,719
NCT02621164 COMPLETED
Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents
SK Chemicals Co., Ltd. n=454
NCT02621177 COMPLETED
Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Healthy Children and Adolescents
SK Chemicals Co., Ltd. n=385
NCT00973700 COMPLETED
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)
Novartis Vaccines n=784
NCT01640327 COMPLETED
Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and Above
Novartis Vaccines n=126
NCT02008344 COMPLETED
Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults
MDVI, LLC n=1,161
NCT02026349 COMPLETED
Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316
MDVI, LLC n=860
NCT02114255 COMPLETED
Effects of BCG on Influenza Induced Immune Response
Radboud University Medical Center n=40
NCT02352584 COMPLETED
A Multicenter, Double-blind, Parallel Phase III Study
Green Cross Corporation n=1,299
NCT00711295 COMPLETED
Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups
Alachua Government Services, Inc. n=3,583
NCT01774032 COMPLETED
H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older
Alachua Government Services, Inc. n=91
NCT01063088 COMPLETED
Adult Safety Study of 2009/2010 Seasonal Influenza Vaccine
Alachua Government Services, Inc. n=211
NCT00943657 COMPLETED
Yearly Strain Variation Study, 2009/2010
Alachua Government Services, Inc. n=110
NCT01138397 COMPLETED
Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)
Sanofi Pasteur, a Sanofi Company n=129
NCT01121822 COMPLETED
Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)
Sanofi Pasteur, a Sanofi Company n=129
NCT01240746 COMPLETED
Study of Quadrivalent Influenza Vaccine Among Children
Sanofi Pasteur, a Sanofi Company n=4,363
NCT01987011 COMPLETED
Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers
Green Cross Corporation n=420
NCT01797029 COMPLETED
A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh
PATH n=1,761
NCT01854632 COMPLETED
Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal
PATH n=1,761
NCT01712984 COMPLETED
Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years
Sanofi Pasteur, a Sanofi Company n=3,360
NCT01346592 COMPLETED
Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age
Novartis Vaccines n=6,104
NCT00866580 WITHDRAWN
A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine
GlaxoSmithKline
NCT01825200 COMPLETED
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
Protein Sciences Corporation n=2,640
NCT00958776 TERMINATED
A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza
BioCryst Pharmaceuticals n=405
NCT00957996 COMPLETED
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
BioCryst Pharmaceuticals n=234
NCT02344134 COMPLETED
Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects
SK Chemicals Co., Ltd. n=1,155
NCT01527825 COMPLETED
Immunogenicity and Safety of Different Dosing Schedules of Trivalent Influenza Vaccine in HIV-infected Pregnant Women
University of Witwatersrand, South Africa n=800
NCT01224795 TERMINATED
A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.
BioCryst Pharmaceuticals n=1
NCT01014364 TERMINATED
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
University of Versailles n=40
NCT01857206 COMPLETED
Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age
Novartis Vaccines n=2,055
NCT00784784 COMPLETED
Zanamivir Versus Trivalent Split Virus Influenza Vaccine
Mount Sinai Hospital, Canada n=64
NCT01162122 COMPLETED
Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects
Novartis Vaccines n=7,109
NCT01810731 WITHDRAWN
Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya
Centers for Disease Control and Prevention
NCT01885117 COMPLETED
Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above
Novartis Vaccines n=125
NCT01209780 COMPLETED
Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age
Novartis Vaccines n=3,116
NCT01310400 COMPLETED
Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children
Crucell Holland BV n=1,356
NCT01229397 COMPLETED
Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V
Crucell Holland BV n=205
NCT01069874 COMPLETED
Trial of Vitamin D Supplementation for the Prevention of Influenza and Other Respiratory Infections (ViDiFlu)
Barts & The London NHS Trust n=240
NCT01053143 COMPLETED
Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India
Sanofi Pasteur, a Sanofi Company n=100
NCT01631110 COMPLETED
Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains
Crucell Holland BV n=110
NCT01050257 COMPLETED
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
Hoffmann-La Roche n=118
NCT01218646 COMPLETED
Study of Quadrivalent Influenza Vaccine Among Adults
Sanofi Pasteur, a Sanofi Company n=739
NCT01229371 COMPLETED
Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers
Crucell Holland BV n=440
NCT01412281 COMPLETED
Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers
Crucell Holland BV n=440
NCT01893177 COMPLETED
Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)
Crucell Holland BV n=110
NCT01546935 WITHDRAWN
Oseltamivir for Influenza Lower Respiratory Tract Infection in Children Under One
University of Oxford
NCT01032395 COMPLETED
Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus
Chiltern Pesquisa Clinica Ltda n=342
NCT01032408 COMPLETED
Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection
Chiltern Pesquisa Clinica Ltda n=154
NCT01580033 COMPLETED
Phase 3 Study of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine
Jiangsu Province Centers for Disease Control and Prevention n=900
NCT01481454 COMPLETED
Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults
Sanofi Pasteur, a Sanofi Company n=1,701
NCT01306682 COMPLETED
Influenza Vaccination of HIV Infected Pregnant Women: Safety and Immunogenicity
University of Witwatersrand, South Africa n=194
NCT01459081 COMPLETED
Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China
Jiangsu Simcere Pharmaceutical Co., Ltd. n=298
NCT01031719 COMPLETED
Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors
Chiltern Pesquisa Clinica Ltda n=59
NCT01554826 COMPLETED
Clinical Trial of the Inactivated Influenza Vaccine (0.25ml Formulation for Pediatric Use)
Hualan Biological Engineering, Inc. n=810
NCT01633749 COMPLETED
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2012/2013 Season
Abbott Biologicals n=120
NCT00976027 TERMINATED
Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older
Sanofi n=9,172
NCT01459952 COMPLETED
A Double-blind, Randomised, Parallel Group,Comparative Study With Rose-hip Liquid and Placebo Given to Healthy Volunteers in the Winter Season Aiming to Evaluate the Occurences of Flu and Catching a Cold
Hyben Vital ApS n=120
NCT01001325 COMPLETED
Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza?
Mount Sinai Hospital, Canada n=468
NCT01428908 COMPLETED
Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children
Jiangsu Province Centers for Disease Control and Prevention n=2,394
NCT00799760 TERMINATED
Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir
Assistance Publique - Hôpitaux de Paris n=541
NCT01147081 COMPLETED
Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011
Novartis Vaccines n=142
NCT01158326 COMPLETED
Evaluation of Efficacy and Safety of Oral Solution Resfenol in Reducing Symptoms of Common Cold And Flu
Hospital de Clinicas de Porto Alegre n=216
NCT01389518 COMPLETED
Efficacy and Safety of Paracetamol, Chlorpheniramine and Phenylephrine in the Treatment of Common Cold and Flu Syndrome
Hospital de Clinicas de Porto Alegre n=146
NCT01422512 COMPLETED
Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects
Novartis Vaccines n=126
NCT00971542 COMPLETED
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age
Novartis Vaccines n=778
NCT00881842 COMPLETED
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 09/10 Season
Abbott Biologicals n=120
NCT00999206 COMPLETED
Study Measuring the Safety, Immunogenicity and Lot Consistency of Cell Derived Influenza Vaccine
Abbott Biologicals n=3,138
NCT01146015 COMPLETED
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010/2011 Season
Abbott Biologicals n=121
NCT00710866 COMPLETED
Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity
British Columbia Centre for Disease Control n=262
NCT00979667 TERMINATED
A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection
Chinese University of Hong Kong n=4
NCT01201902 COMPLETED
A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine
Green Cross Corporation n=592
NCT01016548 COMPLETED
Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy
University Health Network, Toronto n=42
NCT00826709 SUSPENDED
Prospective Evaluation of the Fluid Rapid Influenza Test
Nanogen, Inc. n=1,300
NCT00828100 SUSPENDED
Comparison of Fluid Rapid Influenza and BinaxNOW Influenza A & B
Nanogen, Inc. n=650
NCT00665509 COMPLETED
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 08/09 Season.
Solvay Biologicals n=120
NCT04327791 COMPLETED
COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)
Bassett Healthcare n=15
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only